J Ophthalmol 20112011179412.Maguire AM High KA Auricchio A Wright JF Pierce EA Testa F Mingozzi F Bennicelli JL Ying GS Rossi S Fulton A Marshall KA Banfi S Chung DC Morgan JI Hauck B Zelenaia O Zhu X Raffini L Coppieters F De Baere E Shindler KS Volpe NJ Surace EM Acerra C Lyubarsky A Redmond TM Stone E Sun J McDonnell JW Leroy BP Simonelli F Bennett J Age-dependent effects of RPE65 gene therapy for Leber's congenital amau- rosis a phase 1 dose-escalation trial.

2 Su F Viros A Milagre C Trunzer K Bollag G Spleiss O Reis-Filho JS Kong X Koya RC Flaherty KT Chapman PB Kim MJ Hayward R Martin M Yang H Wang Q Hilton H Hang JS Noe J Lambros M Geyer F Dhomen N Niculescu-Duvaz I Zambon A Niculescu-Duvaz D Preece N Robert L Otte NJ Mok S Kee D Ma Y Zhang C Habets G Burton EA Wong B Nguyen H Kockx M Andries L Lestini B Nolop KB Lee RJ Joe AK Troy JL Gonzalez R Hutson TE Puzanov I Chmielowski B Springer CJ McArthur GA Sosman JA Lo RS Ribas A Marais R RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

N Engl J Med 2009361947-957.Rosell R Moran T Queralt C Porta R Cardenal F Camps C Majem M Lopez-Vivanco G Isla D Provencio M Insa A Massuti B Gonzalez-Larriba JL Paz-Ares L Bover I Garcia-Campelo R Moreno MA Catot S Rolfo C Reguart N Palmero R Sanchez JM Bastus R Mayo C Bertran-Alamillo J Molina MA Sanchez JJ Taron M Screening for epidermal growth factor receptor mutations in lung cancer.

As a result treatment costs may be reduced because the expensive treatment may be restricted to the biomarker-selected patients.

8 Druker BJ Guilhot F O'Brien SG Gathmann I Kantarjian H Gattermann N Deininger MW Silver RT Goldman JM Stone RM Cervantes F Hochhaus A Powell BL Gabrilove JL Rousselot P Reiffers J Cornelissen JJ Hughes T Agis H Fischer T Verhoef G Shepherd J Saglio G Gratwohl A Nielsen JL Radich JP Simonsson B Taylor K Baccarani M So C Letvak L Larson RA Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Front Biosci Landmark ed 2012171165-1183.Loundon N Marlin S Busquet D Denoyelle F Roger G Renaud F Garabedian EN Usher syndrome and cochlear implantation.

N Engl J Med 2009361958-967.Tsao MS Sakurada A Cutz JC Zhu CQ Kamel-Reid S Squire J Lorimer I Zhang T Liu N Daneshmand M Marrano P da Cunha SG Lagarde A Richardson F Seymour L Whitehead M Ding K Pater J Shepherd FA Erlotinib in lung cancer - molecular and clinical predictors of outcome.

N Engl J Med 2005352786-792.Engelman JA Zejnullahu K Mitsudomi T Song Y Hyland C Park JO Lindeman N Gale CM Zhao X Christensen J Kosaka T Holmes AJ Rogers AM Cappuzzo F Mok T Lee C Johnson BE Cantley LC Janne PA MET amplifi- cation leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Gene mutations of CYP1B1 and LTBP2 are associated with congenital glaucomas 45 mutations of MYOC OPTN and WDR36 are associated with primary glaucomas allowing genetic analyses to better predict disease probability 45 46.

N Engl J Med 2005353123-132.Sharma SV Bell DW Settleman J Haber DA Epidermal growth factor receptor mutations in lung cancer.

